(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of 15.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Xencor's revenue in 2026 is $97,360,000.On average, 16 Wall Street analysts forecast XNCR's revenue for 2026 to be $6,155,161,158, with the lowest XNCR revenue forecast at $1,017,222,697, and the highest XNCR revenue forecast at $13,178,668,689. On average, 16 Wall Street analysts forecast XNCR's revenue for 2027 to be $9,455,277,738, with the lowest XNCR revenue forecast at $1,089,881,461, and the highest XNCR revenue forecast at $30,288,324,798.
In 2028, XNCR is forecast to generate $10,637,836,194 in revenue, with the lowest revenue forecast at $4,219,324,087 and the highest revenue forecast at $26,352,147,466.